i卡會員

The global 3D bioprinting market, valued at 1.3 billion USD in 2024, is expected to reach USD 2.4 billion by 2029. Driven by demand for personalized medicine and improved drug testing models, bioprinting enables the creation of patient-specific tissues, offering an ethical alternative to traditional methods. Leading companies like Organovo, Brinter, and 3D Systems are advancing bioprinting in drug testing, regenerative medicine, and space research. With strong investments and technological innovations, the market is set for continued growth, positioning bioprinting as a key player in personalized healthcare.

【Content outline】

• A. The Growing Impact of 3D Bioprinting in Personalized Medicine and Drug Discovery
• B. The U.S. 3D bioprinting market is advancing drug discovery with accurate, cost-effective models that surpass traditional methods
  • I. Drug research has held the highest revenue among research applications of 3D BIOPRINTING MARKET from 2022 to 2024
  • II. U.S. Drug Research Revenue
• C. Case Studies: Organovo, Brinter, and 3D Systems use distinct strategies to innovate and compete in the evolving biomedical research and healthcare market
  • I. Organovo Holdings Inc.: Specialization in Functional 3D Bioprinting
  • II. Brinter: A Modular Bioprinting Innovator with Cross-Industry Impact
  • III. 3D Systems: Diversifying Growth through Bioprinting and Strategic Acquisitions
• IEKView

【Chart outline】

• Figure 1、Global 3D Bioprinting Market for Research Applications, By Type
• Figure 2、Global 3D Bioprinting Drug Research Market
• Figure 3、U.S. 3D Bioprinting Drug Research Market Revenue